Gufic Biosciences Invests USD 50,000 in Selvax Pty Ltd for Cancer Treatment
Gufic Biosciences invested USD 50,000 in Selvax Pty Ltd by acquiring 3,78,350 shares. Selvax is an Australian biotech firm developing novel immunology-based treatments for solid tumors. This strategic investment diversifies Gufic Biosciences into healthcare and biotechnology.
The investment amount is relatively small, but it represents a strategic diversification into a high-growth sector with potential long-term benefits.
The investment in a biotechnology company developing novel cancer treatments is a positive strategic move for diversification and future growth.
Gufic Biosciences Limited has announced a further investment of USD 50,000 in Selvax Pty Ltd, an Australian biotechnology company. This investment, made on April 28, 2026, involved the subscription of 3,78,350 ordinary shares at AUD 0.20 per share.
Selvax is engaged in developing a novel immunology-based treatment for large solid tumors, with potential applications in both human and veterinary oncology. The company's technology aims to provide better outcomes with lower toxicity, overcome drug resistance, and potentially treat metastatic cancers. Selvax was incorporated on August 14, 1987, and is based in Western Australia.
The investment is a strategic move for Gufic Biosciences to diversify into the healthcare and biotechnology sector, gain access to proprietary technology, and participate in the development of advanced cancer treatments. This transaction does not fall under related party transactions, and Gufic Biosciences now holds 16,85,350 ordinary shares in Selvax post-acquisition. The transaction was completed on April 28, 2026, with cash consideration.
What to do with a filing like this
Gufic Biosciences Limited filed this with the NSE as a statutory disclosure, categorised under other corporate actions. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gufic Biosciences Limited. Read the original for the full detail.